Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
All GLP-1 RAs including the dual agent tirzepatide and oral semaglutide demonstrated CV safety
Severe Physical Limitations: Difficulty with daily tasks, such as walking short distances, climbing stairs, or engaging in family activities
Common side effects include nausea, vomiting, diarrhea, and constipation, with potential serious risks including pancreatitis and gallbladder disease
doi: 10.1016/j.freeradbiomed.2009.12.022 44 CircuM
McGraw-Hill / Lange rxlist.com (Tragenta ) Alogliptin Trade Name: Nesina Mechanism of Action: a DPP-4 inhibitor, similar to Sitagliptin Pharmacokinetics: does not undergo significant metabolism, and is mostly excreted unchanged in the urine (76%) and feces (13%) dosage should be reduced in patients with moderate to severe renal impairment References: Masharani U, Kroon L (2024): Pancreatic Hormones & Antidiabetic Drugs (Chapter 41)
